Casgevy gains UK label expansion for younger patient population
Vertex Pharmaceuticals and CRISPR Therapeutics have secured a label expansion for their gene editing therapy Casgevy (exagamglogene autotemcel) from UK…
News
Eli Lilly’s tirzepatide outperforms big pharma companies in Q3
Glenmark opens Allentown distribution hub in US
Dren Bio raises $350m for dibotatug clinical development
RFK Jr backs compounding of six unapproved peptides in new policy
UK Budget light on life sciences but more doors open for biotech startups
Enthorin and Rumi sign agreement for FXS therapy
Formation Bio launches $600m drug development fund
